Click here to go to the previous page
Breakthroughs in Medicinal Chemistry and Chemical Biology in the Czech Republic: Unique Opportunities for Drug Research, Development and Joint Venture
Program Code:
3399
Date:
Tuesday, May 19, 2009
Time:
4:00 PM to 4:30 PM
EST
SPEAKER
(S):
Tomas Cihlar, Gilead Sciences, Inc
"Although the working draft of the human genome was released in 2000 and a complete one in 2003, therapeutics today are still based on very few drugs directed against approximately just 300-400 gene targets. However, the sequencing of the genome has revealed 30,000-40,000 human genes, encoding up to a quarter of a million potential drug targets. This opens the potential for an era of directed drug discovery that will see thousands of new compounds developed annually. Biopharmaceutical statistics show that approximately 5-10 thousands new molecules will result in one registered drug on the market. Our experience and data from major chemical groups in the Czech Republic indicate that we synthesize around 5-10.000 new structures per year in the country, although majority of them are not tested for biological activity or performed tests are limited to one or two major biological activities. "
|
Jiri Krechl, Czechinvest, Investment and Business Development Agency